IN2014MN01907A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01907A IN2014MN01907A IN1907MUN2014A IN2014MN01907A IN 2014MN01907 A IN2014MN01907 A IN 2014MN01907A IN 1907MUN2014 A IN1907MUN2014 A IN 1907MUN2014A IN 2014MN01907 A IN2014MN01907 A IN 2014MN01907A
- Authority
- IN
- India
- Prior art keywords
- composition
- festinavir
- nevirapine
- lamivudine
- retroviruses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1907MUN2014 IN2014MN01907A (es) | 2012-03-05 | 2013-03-05 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN583MU2012 | 2012-03-05 | ||
| PCT/GB2013/000092 WO2013132208A1 (en) | 2012-03-05 | 2013-03-05 | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine |
| IN1907MUN2014 IN2014MN01907A (es) | 2012-03-05 | 2013-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01907A true IN2014MN01907A (es) | 2015-07-10 |
Family
ID=47884388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1907MUN2014 IN2014MN01907A (es) | 2012-03-05 | 2013-03-05 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150104511A1 (es) |
| EP (1) | EP2822560A1 (es) |
| JP (1) | JP2015509524A (es) |
| KR (1) | KR20140138837A (es) |
| CN (1) | CN104203244A (es) |
| AU (1) | AU2013229274A1 (es) |
| BR (1) | BR112014021927A2 (es) |
| CA (1) | CA2866133A1 (es) |
| IN (1) | IN2014MN01907A (es) |
| MX (1) | MX2014010337A (es) |
| RU (1) | RU2014140177A (es) |
| WO (1) | WO2013132208A1 (es) |
| ZA (1) | ZA201406495B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9688666B2 (en) * | 2013-02-07 | 2017-06-27 | Tobira Therapeutics, Inc. | Lamivudine salts |
| EP3153157A1 (en) | 2015-10-09 | 2017-04-12 | Teva Pharmaceutical Works Private Limited Company | Pharmaceutical composition for prolonged release of nevirapine |
| TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| KR102587510B1 (ko) | 2018-02-15 | 2023-10-11 | 길리애드 사이언시즈, 인코포레이티드 | 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도 |
| KR20230141905A (ko) * | 2018-07-16 | 2023-10-10 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
| BR112021014576A2 (pt) | 2019-01-25 | 2021-10-05 | Brown University | Composições e métodos para tratamento, prevenção ou reversão de inflamação e distúrbios associados à idade |
| CA3235937A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69206876T3 (de) | 1991-05-16 | 2004-08-12 | Glaxo Group Ltd., Greenford | Nukleosidanalogen enthaltende Antiviren-Zubereitungen |
| GB9622681D0 (en) | 1996-10-31 | 1997-01-08 | Glaxo Group Ltd | Pharmaceutical compositions |
| DE69805001T2 (de) * | 1997-12-05 | 2002-08-22 | Alza Corp | Osmotische darreichungsform mit zwei mantelschichten |
| AR016169A1 (es) | 1998-01-16 | 2001-06-20 | Medivir Ab | Compuesto, composicion farmaceutica que lo comprende y uso del mismo en la fabricacion de un medicamento para el tratamiento o profilaxis del vih. |
| GB9809213D0 (en) | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| WO2004087169A1 (en) | 2003-03-27 | 2004-10-14 | Boehringer Ingelheim International Gmbh | Antiviral combination of nevirapine and a further antiretroviral compound |
| ATE484284T1 (de) * | 2005-08-31 | 2010-10-15 | Cipla Ltd | Pharmazeutische kombinationen mit lamivudin, stavudin und nevirapin |
| CN101784263B (zh) * | 2007-06-08 | 2012-11-07 | 贝林格尔.英格海姆国际有限公司 | 奈韦拉平的延长释放制剂 |
-
2013
- 2013-03-05 US US14/382,444 patent/US20150104511A1/en not_active Abandoned
- 2013-03-05 EP EP13709491.8A patent/EP2822560A1/en not_active Withdrawn
- 2013-03-05 CN CN201380012366.4A patent/CN104203244A/zh active Pending
- 2013-03-05 RU RU2014140177A patent/RU2014140177A/ru not_active Application Discontinuation
- 2013-03-05 KR KR20147027819A patent/KR20140138837A/ko not_active Application Discontinuation
- 2013-03-05 BR BR112014021927A patent/BR112014021927A2/pt not_active IP Right Cessation
- 2013-03-05 AU AU2013229274A patent/AU2013229274A1/en not_active Abandoned
- 2013-03-05 IN IN1907MUN2014 patent/IN2014MN01907A/en unknown
- 2013-03-05 CA CA2866133A patent/CA2866133A1/en not_active Abandoned
- 2013-03-05 MX MX2014010337A patent/MX2014010337A/es unknown
- 2013-03-05 WO PCT/GB2013/000092 patent/WO2013132208A1/en active Application Filing
- 2013-03-05 JP JP2014560438A patent/JP2015509524A/ja active Pending
-
2014
- 2014-09-04 ZA ZA2014/06495A patent/ZA201406495B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150104511A1 (en) | 2015-04-16 |
| RU2014140177A (ru) | 2016-04-27 |
| JP2015509524A (ja) | 2015-03-30 |
| MX2014010337A (es) | 2014-11-14 |
| AU2013229274A1 (en) | 2014-09-04 |
| KR20140138837A (ko) | 2014-12-04 |
| EP2822560A1 (en) | 2015-01-14 |
| WO2013132208A8 (en) | 2013-11-07 |
| BR112014021927A2 (pt) | 2019-09-24 |
| ZA201406495B (en) | 2016-03-30 |
| WO2013132208A1 (en) | 2013-09-12 |
| CA2866133A1 (en) | 2013-09-12 |
| CN104203244A (zh) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2013MU01749A (es) | ||
| IN2014MN01907A (es) | ||
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| PH12015501156A1 (en) | Pharmaceutical compositions | |
| PH12014501738A1 (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| MX358099B (es) | Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos. | |
| TN2015000185A1 (en) | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group | |
| UA113651C2 (xx) | Макроциклічні пурини для лікування вірусних інфекцій | |
| EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
| PH12016501968A1 (en) | Novel macrocyclic compounds | |
| CY1119957T1 (el) | Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος | |
| CY1118074T1 (el) | Ανθελονοσιακοι παραγοντες | |
| DOP2017000086A (es) | Composiciones farmacéuticas de acción prolongada | |
| MX2018006773A (es) | Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina. | |
| PH12015502746A1 (en) | Prodrug derivatives of substituted triazolopyridines | |
| CY1118913T1 (el) | Νεοι ανθελονοσιακοι παραγοντες | |
| BR112017003252A2 (pt) | terapia com anticorpos contra hiv como substituto de tratamento | |
| PH12015500322A1 (en) | Tris(hetero)arylpyrazoles and use thereof | |
| IN2013CH05288A (es) | ||
| JO3641B1 (ar) | تركيبة مضادات الفيروسات القهقرية | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| CY1116711T1 (el) | Νεοι ανθελονοσιακοι παραγοντες |